TrialCancer control : journal of the Moffitt Cancer Center

An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.

Dionisia Quiroga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.